Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus

Gynecological Endocrinology

Volumn 23, Issue 6, 2007, Pages 356-360

  Schöndorf, Thomas ^a,b,f   Lübben, Georg ^c   Hoopmann, Markus ^b   Borchert, Marcus ^a   Forst, Thomas ^a   Hohberg, Cloth ^a   Löbig, Mirjam ^a   Armbruster, Franz Paul ^d   Roth, Werner ^a   Grabellus, Martin ^a   Pfützner, Andrzas ^a,e  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Takeda Pharma GmbH   (Germany)

^d IMMUNDIAGNOSTIK AG   (Germany)

^e University of Applied Science   (Germany)

^f IKFE GmbH   (Germany)

Author keywords

Coagulation; Heart protection; Postmenopause; Type 2 diabetes

Indexed keywords

FIBRINOGEN; GLIMEPIRIDE; PIOGLITAZONE; RELAXIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; RELAXIN; SEX FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34447115602     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701447998     Document Type: Article

References (29)

1. Stratmann B, Tschöpe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005;2:16-23.
2. Vaidyula VR, Rao AK, Mozzoli M, Homo C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006;55:202-208.
3. Banga JD. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2002;2:75-86.
4. Vigilance JE, Reid HL. Glycaemic control influences peripheral blood flow and haemorrhagial variables in patients with diabetes. Clin Hemorheol Microcirc 2005;33:337-346.
5. Tahbaz F, Kreis I, Calvert D. An audit of diabetes control, dietary management and quality of life in adults with type diabetes mellitus, and a comparison with nondiabetic subjects. J Hum Nutr Diet 2006;19:3-11.
6. Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006;106:16-20.
7. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:1776-1783.
8. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004;25:205-234.
9. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001;15:2187-2195.
10. Wilson BC, Milne P, Saleh TM. Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci 2005;1041:223-238.
11. Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann N Y Acad Sci 2005;1041:441-443.
12. Perna AM, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, Bigazzi M, Pieroni C, Bani Sacchi T, Bani D. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J 2005;19:1525-1527.
13. Bacchari MC, Calami F. Relaxin: new functions for an old peptide. Curr Protein Pept Sci 2004;5:9-18.
14. Failli P, Nistri S, Mazzetti L, Chiapini L, Bani D. Effects of relaxin on vascular smooth muscle and endothelial cells in normotensive and hypertensive rats. Ann N Y Acad Sci 2005;1041:311-313.
15. Cohen RA. Role of nitric oxide in diabetic complications. Am J Ther 2005;12:499-502.
16. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-1931.
17. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-2531.
18. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer Study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005;37:510-515.
19. Concannon PW, Gimpel T, Newton L, Castrace VD. Postimplantation increase in plasma fibrinogen concentration with increase in relaxin concentration in pregnant dogs. Am J Vet Res 1996;57:1382-1385.
20. Concannon P, Tsutsui T, Shille V. Embryo development, hormonal requirements and maternal responses during canine pregnancy. J Reprod Fertil Suppl 2001;57:169-179.
21. Nasr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol Endocrinol 1998;12:43-59.
22. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005;28:2472-2479.
23. Tracy RP. Atherogenesis and coronary heart disease. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. 3rd ed, Chichester (UK): Wiley; 2004. pp 1437-1447.
24. Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM, Woodcock EA, Summers RJ, Tregear GW, Bathgate RA, et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007;148:1582-1589.
25. Lekgabe ED, Royce SG, Hewitson TD, Tang ML, Zhao C, Moore XL, Tregear GW, Bathgate RA, Du XJ, Samuel CS. The effects of relaxin and estrogen deficiency on collagens and hypertrophy on nonreproductive organs. Endocrinology 2006;147:5575-5583.
26. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005;54:1236-1242.
27. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharmaceut Design 2005;11:2331-2365.
28. Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med 2005;22:1657-1662.
29. Schneider DJ, Keating FK, Baumann PQ, Whitaker DA, Sobel BE. Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus. Coron Artery Dis 2006;17:57-61.